Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With A New Director Elect, NICE Is On A Mission To Elevate Medtech

Executive Summary

A refreshed NICE, soon to get a new medtech director, has set out a series of priorities that show an intent to bring medtech closer to the center of its activities.

You may also be interested in...



UK’s Early Value Assessment Pilot Is ‘Catalyst’ For Wider Change - NICE

NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.

Here Comes The NICE Revolution – Agility And Speed Will Drive UK HTA Into A New Era

Evolving health care demands, digital innovation and the need to work within tighter budgets have prompted the UK’s NICE to reset its strategy for the coming five years.

UK Plugs Into ‘Golden Period’ For Medtech Innovation

The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel